Special Issue

Advanced Research into Adipose⊠Derived Stem Cells

Message from the Guest Editors

Adipose-derived stem cells (ASCs), abundant in the human body, can be harvested with minimal invasiveness, and they are becoming gaining increasingly widespread use in the treatment of various diseases. The regenerative properties of these cells are widely known. A recent study offers many strategies to obtain 3D cell spheroids of ASCs with different techniques. As very innovative elements, their clinical applications in regenerative medicine include the use of bio\printers and bioreactors to create ad personam organ and replacement tissue or the use of engineered vesicles. It is important to find innovative techniques that require the least manipulation and the produce highest cell yields for prompt use in medicine. This Special Issue will serve as a reference text for researchers and academics, as well as those studying ASC properties and their potential clinical uses. Researchers working in the field of regenerative medicine and basic and translation-related studies are encouraged to publish their recent findings in this Special Issue of *Biomedicines*.

Guest Editors

Dr. Anna Barbara Di Stefano

BIOPLAST-Laboratory of Biology and Regenerative Medicine-PLASTic Surgery, Dipartimento di Discipline Chirurgiche, Oncologiche e Stomatologiche, Università degli Studi di Palermo, via del Vespro 129, 90127 Palermo, Italy

Dr. Mara Franza

Department of Precision Medicine in Medical, Surgical and Critical Care (Me. Pre. C.C.), Plastic and Reconstructive Surgery, Università degli Studi di Palermo, Palermo, Italy

Deadline for manuscript submissions

closed (30 June 2025)



an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed



mdpi.com/si/204566

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +4161 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines





an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed





About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access iournal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

- Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
- 2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).